- Disease
- Complement 3 Glomerulopathy (C3G)
- IgA Nephropathy
- Immunoglobulin A Nephropathy (IgAN)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- chronic graft-versus-host disease (cGVHD)
- Chronic Lymphocytic Leukemia,SLL,MCL
- Waldenström's macroglobulinemia (WM)
- Acute myeloid leukemia
- Anemia due to chronic kidney disease (CKD)
- Anemia in Chronic Kidney Disease (CKD) Patients on Dialysis
- Aggressive Systemic Mastocytosis (ASM)
- FLT3 mutation AML
- Myeloproliferative Disorders
- Hyperprolactinemia
- Parkinson's Disease
- Prolactinomas
- Nonalcoholic steatohepatitis (NASH)
- Treat essential thrombocythemia (ET)
- High-risk myelofibrosis
- Positive acute myeloid leukemia
- Chronic graft-versus-host disease
- leukaemia
- Chronic immune (idiopathic) thrombocytopenic purpura
- Hronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- Small lymphocytic lymphoma (SLL)
Related News
-
LuciTala Side Effects — Blood Count Changes and Clinical Trial Safety
Introduction Cancer medicines can affect patients in different ways. Some side effects…
2026-11-06
-
LuciTala Dosage and Administration — How to Take Talazoparib Safely
Introduction Taking an oral cancer medicine at home can be convenient, but…
2026-11-04
-
LuciTala (Talazoparib): How PARP Inhibition Works in Certain Cancers
Introduction A cancer diagnosis often brings difficult questions about treatment, expected outcomes…
2026-11-02
-
LuciNav Side Effects — Hyperglycaemia, Risks and Patient Monitoring
Introduction Targeted cancer medicines are designed to act on particular biological pathways,…
2026-10-31
-
How to Take LuciNav Safely — Dosage, Monitoring and Precautions
Introduction Taking an oral cancer medicine involves more than following a daily…
2026-10-26
-
LuciNav (Inavolisib) for PIK3CA-Mutated Breast Cancer
Introduction A breast cancer diagnosis can bring uncertainty, particularly when the disease…
2026-10-21



